Early-stage Fundraising Target BD efforts toward securing additional non-dilutive and early-stage funding opportunities, such as SBIR/STTR grants and foundation grants, leveraging Anagin's past grant success to build credibility with research-focused funders and potential strategic investors.

Clinical Pipeline Fit Position partnerships around CoDevelopment or sponsored research for PTSD, TBI, depression, neuropathic pain, and neurodegenerative diseases, highlighting first-in-class approaches and the ability to provide specialized preclinical and translational expertise.

Small Team Advantage Offer high-touch collaboration models with lean partner integration, emphasizing rapid decision cycles, flexible engagement terms, and access to nimble project management suitable for a biotech startup–sized organization.

Tech-enabled Ops Leverage the company’s modern tech stack and cloud-enabled workflows to propose efficient data sharing, secure collaboration, and scalable research operations services that align with regulatory compliance needs for external partners.

Industry Alignment Target mid-to-large pharma and biotech players exploring PTSD, TBI, and neurodegenerative programs, offering strategic advisory, biomarker validation support, and access to specialized neuroscience expertise to complement large portfolios.